Title: Co-trimoxazole Monograph for Professionals - Drugs.com
Headings: Co-trimoxazole
Co-trimoxazole
Introduction
Uses for Co-trimoxazole
Acute Otitis Media
GI Infections
Respiratory Tract Infections
Urinary Tract Infections (UTIs)
Brucellosis
Burkholderia Infections
Cholera
Cyclospora Infections
Granuloma Inguinale (Donovanosis)
Isosporiasis
Listeria Infections
Mycobacterial Infections
Nocardia Infections
Pertussis
Plague
Pneumocystis jiroveci (Pneumocystis carinii) Pneumonia
Toxoplasmosis
Typhoid Fever and Other Salmonella Infections
Wegener’s Granulomatosis
Whipple’s Disease
Co-trimoxazole Dosage and Administration
Administration
IV Administration
Dilution
Rate of Administration
Dosage
Pediatric Patients
Acute Otitis Media
Oral
GI Infections
Shigella Infections
Urinary Tract Infections (UTIs)
Oral
Severe UTIs
Brucellosis†
Oral
Cholera†
Oral
Cyclospora Infections†
Oral
Granuloma Inguinale (Donovanosis)†
Oral
Isosporiasis†
Oral
Pertussis†
Oral
Plague†
Postexposure Prophylaxis†
Pneumocystis jiroveci (Pneumocystis carinii) Pneumonia
Treatment
Primary Prophylaxis in Infants and Children
Prevention of Recurrence (Secondary Prophylaxis) in Infants and Children
Primary and Secondary Prophylaxis in Adolescents
Toxoplasmosis†
Primary Prophylaxis in Infants and Children†
Primary Prophylaxis in Adolescents†
Oral
Adults
GI Infections
Treatment of Travelers’ Diarrhea
Prevention of Travelers’ Diarrhea
Shigella Infections
Respiratory Tract Infections
Acute Exacerbations of Chronic Bronchitis
Urinary Tract Infections (UTIs)
Oral
Severe UTIs
Cholera†
Oral
Cyclospora Infections†
Oral
Granuloma Inguinale (Donovanosis)†
Oral
Isosporiasis†
Oral
Mycobacterial Infections†
Mycobacterium marinum Infections
Pertussis†
Oral
Pneumocystis jiroveci (Pneumocystis carinii) Pneumonia
Treatment
Primary Prophylaxis
Prevention of Recurrence (Secondary Prophylaxis)
Toxoplasmosis†
Primary Prophylaxis
Wegener’s Granulomatosis†
Oral
Special Populations
Renal Impairment
Geriatric Patients
Detailed Co-trimoxazole dosage information
Cautions for Co-trimoxazole
Contraindications
Warnings/Precautions
Warnings
Severe Reactions related to the Sulfonamide Component
Superinfection/Clostridium difficile-associated Colitis
Sensitivity Reactions
Hypersensitivity Reactions
Sulfite Sensitivity
General Precautions
Patients with Folate Deficiency or G6PD Deficiency
Patients with Pneumocystis jiroveci (Pneumocystis carinii) Pneumonia
Laboratory Monitoring
Selection and Use of Anti-infectives
Specific Populations
Pregnancy
Lactation
Pediatric Use
Geriatric Use
Hepatic Impairment
Renal Impairment
Common Adverse Effects
Interactions for Co-trimoxazole
Specific Drugs and Laboratory Tests
Co-trimoxazole drug interactions (more detail)
Co-trimoxazole Pharmacokinetics
Absorption
Bioavailability
Distribution
Extent
Plasma Protein Binding
Elimination
Metabolism
Elimination Route
Half-life
Special Populations
Stability
Storage
Oral
Tablets
Suspension
Parenteral
Concentrate for Injection
Compatibility
Parenteral
Solution CompatibilityHID
Drug Compatibility
Actions and Spectrum
Advice to Patients
Preparations
Frequently asked questions
More about Co-trimoxazole (sulfamethoxazole / trimethoprim)
Consumer resources
Professional resources
Other brands
Related treatment guides

Content: A parenteral regimen should be used if systemic infection is suspected. Role of anti-infectives in treatment of hemorrhagic colitis caused by shiga toxin-producing E. coli † (STEC; formerly known as enterohemorrhagic E. coli) is unclear; most experts would not recommend use of anti-infectives in children with enteritis caused by E. coli 0157: H7. Treatment of GI infections caused by Yersinia enterocolitica † or Y. pseudotuberculosis †. These infections usually are self-limited, but IDSA, AAP, and others recommend anti-infectives for severe infections, when septicemia or other invasive disease occurs, and in immunocompromised patients. Other than decreasing the duration of fecal excretion of the organism, a clinical benefit of anti-infectives in management of enterocolitis, pseudoappendicitis syndrome, or mesenteric adenitis caused by Yersinia has not been established. Respiratory Tract Infections
Treatment of acute exacerbation of chronic bronchitis caused by susceptible S. pneumoniae or H. influenzae when the clinician makes the judgment that the drug offers some advantage over use of a single anti-infective. A drug of choice for treatment of upper respiratory tract infections and bronchitis caused by H. influenzae; an alternative to penicillin G or penicillin V for treatment of respiratory tract infections caused by S. pneumoniae.